The estimated Net Worth of Tiffany Olson is at least $216 Tausend dollars as of 1 July 2024. Ms. Olson owns over 830 units of HeartBeam Inc stock worth over $38,774 and over the last 16 years she sold BEAT stock worth over $0. In addition, she makes $176,951 as Independent Director at HeartBeam Inc.
Sign up
Ms. Olson BEAT stock SEC Form 4 insiders trading
Tiffany has made over 8 trades of the HeartBeam Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 830 units of BEAT stock worth $1,868 on 1 July 2024.
The largest trade she's ever made was exercising 8,636 units of HeartBeam Inc stock on 25 May 2024 worth over $19,431. On average, Tiffany trades about 1,014 units every 46 days since 2009. As of 1 July 2024 she still owns at least 17,233 units of HeartBeam Inc stock.
You can see the complete history of Ms. Olson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Tiffany Olson biography
Tiffany P. Olson serves as Independent Director of the Company. Ms. Olson has been the president of Nuclear & Precision Health Solutions at Cardinal Health since 2013, which develops, manufactures, compounds, dispenses and delivers over ten million, time-critical, patient specific doses annually. Prior to Cardinal Health, Ms. Olson was President of NaviMed, a company focused on personalizing medicine through innovative diagnostics. She also worked for Eli Lilly and Company, where she was tasked with leading the effort to formulate the strategy to create and commercialize diagnostics and companion diagnostics. Ms. Olson also worked for Roche Diagnostics for many years, where she attained the position of President and Chief Executive Officer of Roche Diagnostics Corporation. She was the first woman to receive the Life Science Alley Luminary Award, recognizing her “rich career in medical diagnostics…exceptional reputation as a leader and her vision to drive both innovation and value for personalized medicine.” In 2013, she received the “Woman of Wellness Award” for her extraordinary contributions through her volunteer work in oncology.
What is the salary of Tiffany Olson?
As the Independent Director of HeartBeam Inc, the total compensation of Tiffany Olson at HeartBeam Inc is $176,951. There are 11 executives at HeartBeam Inc getting paid more, with Joseph Capper having the highest compensation of $4,133,160.
How old is Tiffany Olson?
Tiffany Olson is 59, she's been the Independent Director of HeartBeam Inc since 2019. There are 12 older and 5 younger executives at HeartBeam Inc. The oldest executive at HeartBeam Inc is Robert Rubin, 74, who is the Independent Director.
What's Tiffany Olson's mailing address?
Tiffany's mailing address filed with the SEC is C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD, SUITE 401, FRIENDSWOOD, TX, 77546.
Insiders trading at HeartBeam Inc
Over the last 11 years, insiders at HeartBeam Inc have traded over $23,124,978 worth of HeartBeam Inc stock and bought 31,500 units worth $221,145 . The most active insiders traders include Joseph H Capper, Heather C Getz und Willem Elfrink. On average, HeartBeam Inc executives and independent directors trade stock every 32 days with the average trade being worth of $55,046. The most recent stock trade was executed by Urioste George De on 6 September 2024, trading 1,674 units of BEAT stock currently worth $3,917.
What does HeartBeam Inc do?
heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.
What does HeartBeam Inc's logo look like?
Complete history of Ms. Olson stock trades at HeartBeam Inc, MiMedx Inc und Castle Biosciences
HeartBeam Inc executives and stock owners
HeartBeam Inc executives and other stock owners filed with the SEC include:
-
Joseph Capper,
President, Chief Executive Officer, Director -
Heather Getz,
Chief Financial Officer, Executive Vice President, Chief Administrative Officer -
Fred Broadway,
President, BioTel Heart -
Daniel Wisniewski,
Senior Vice President - Technical Operations -
Kirk Gorman,
Independent Chairman of the Board -
Rebecca Rimel,
Independent Director -
Anthony Conti,
Independent Director -
Joseph Frick,
Independent Director -
Stephan Rietiker,
Director -
Robert Rubin,
Independent Director -
Colin Hill,
Independent Director -
Tiffany Olson,
Independent Director -
Laura Dietch,
Independent Director -
Dr. Branislav Vajdic Ph.D.,
Founder, CEO & Director -
Richard D. Brounstein,
Chief Financial Officer -
Manish Wadhwa,
Chief Medical Officer -
Andrei Stoica,
Chief Technology Officer -
Dr. Peter J. Fitzgerald FACC, M.D., Ph.D.,
Chief Medical Officer -
Ken Persen,
Chief Technology Officer -
Dr. Jon Hunt Ph.D.,
Exec. VP & Chief Bus. Officer -
Alexei Shvilkin M.D.,
Chief Medical Officer -
Dr. Dorin Panescu Ph.D.,
Chief Technical Officer -
Alan Baumel,
Chief Operating Officer -
Richard M. Ferrari,
Exec. Chairman -
George Hrenko,
Senior Vice President -
Stephen Rietiker,
Director -
Michael Geldart,
Senior Vice President -
Ronald A Ahrens,
Director -
Eric N Prystowsky,
Director -
Peter Ferola,
SVP & General Counsel -
Kenneth Warwick Iii Nelson,
Director -
Mark E Strome,
10% owner -
Michael R Jaff,
Director -
Willem Elfrink,
Director -
Marga Ortigas Wedekind,
Director -
Urioste George De,
Director -
Richard Ferrari,
Director -
Jon Patrick Hunt,
Chief Business Officer -
Richard Brounstein,
Chief Financial Officer -
Alan Baumel,
Chief Operating Officer -
Kenneth Harry Persen,
Chief Technology Officer -
Robert Paul Eno,
President -
Branislav Vajdic,
CHIEF EXECUTIVE OFFICER